Please assess the completion status of the following clinical trial:

Trial Title: Double-Blind Placebo-Controlled CIN Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Inpatients scheduled for CT scan of abdomen and/or pelvis~* Had surgery in the last 4 weeks~* Stable renal function (based on serum creatinine-last two lab values +/- 0.3 of each other, with most recent within 5 days of CT)~* Suspected infection or fluid collection in abdomen and/or pelvis~Exclusion Criteria:~* Pregnant~* Severe Allergy (anaphylaxis) to contrast~* Dialysis in last 7 days~* Received intravascular iodinated contrast in last 48 hours~* CT of abdomen and pelvis in last 7 days shows no fluid collection~* Prisoners~* CT ordered for an indication that requires (eg, CT angiogram) or contraindicates (eg, renal stone CT) the administration of intravascular contrast

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Iopamidol 300 (Contrast) (Type: ACTIVE_COMPARATOR): Subjects scheduled for a clinical CT will be randomized to receive weight-based low-osmolality iodinated contrast with the CT. All subjects will receive a minimum of 1 mL/kg/hr of isotonic volume expansion for at least three hours before and three hours after the CT.
- Placebo (Normal Saline) (Type: PLACEBO_COMPARATOR): Subjects scheduled for a standard of care CT will be randomized to receive weight-based normal saline instead of contrast material with the CT. All subjects will receive a minimum of 1 mL/kg/hr of isotonic volume expansion for at least three hours before and three hours after the CT.

Based on this trial design, predict the completion outcome and termination type (if applicable).